Drug companies violate the rules to find votes, buy tickets and write accounts | Four ministries will focus on combating pseudo-CSO
On September 26th, the pharmaceutical network was fully implemented, the Jinsan system was continuously upgraded, the tax invoice management was fully monitored, and the VAT declaration was upgraded. Some pharmaceutical companies used the illegal bills to find out the votes, buy tickets, and fake CSO. Invoicing, the cost of the withdrawal will not work! The compliance of the traditional payment method for pharmaceutical companies faces enormous challenges! The newly established shell company receives the invoice from the tax bureau, and the fee for the invoice is violently opened without business. Tax 'Zero Tolerance'! How to move towards true compliance and legalization, and achieve compliance operation of marketing outsourcing (CSO)? How to confirm the authenticity of service services such as market service fees, technical consulting fees, and promotion fees? How to regulate? How is the invoice content compliant?
Recently, the State Administration of Taxation, Hubei Provincial Taxation Bureau issued medicine Consultation on the special risk response work of the industry, the notice pointed out that after the implementation of the two-vote system, the ticket-issuing company disappeared. In order to cope with the two-vote system, a large number of 'consulting management services', 'medical technology consulting', 'information technology', etc. The title of the third-party service company appeared. The Audit Commission has characterized the invoicing of such enterprises as 'passing money laundering'! The industry is called CSO, which is actually a pseudo-CSO, which will be hit hard!
In November last year, the China Tax News published a national tax official in Hebei, authoring the 'two-vote system, the cost of sales of pharmaceutical companies is so high?' Directly refers to the two-vote system of pharmaceuticals, causing the sales revenue and expenses of pharmaceutical companies to skyrocket! Market service fees, technical consulting fees Service items such as promotion fees have become the essence of 'service outerwear' but 'virtual money laundering'! Pseudo-CSO is difficult to sustain!
In August, the State Administration of Taxation, the Ministry of Public Security, the General Administration of Customs and the four ministries and commissions of the People's Bank of China jointly deployed 'two years of special action to crack down on the infringement of value-added tax invoices and defrauding export tax rebates.' Four ministries will take the lead in a zero-tolerance attitude. Just hit ', targeted remediation, for the 'fake business' that has no actual business operation only for virtual invoicing. The pharmaceutical industry pseudo-CSO or become a key target!
After the two-vote system, in recent years, the pharmaceutical industry has set up tens of thousands of CSO companies. The sales of gold has not disappeared in the short term. The professional academics have not yet been formed. Can the pseudo-CSO model continue to do so? 'Pharmaceutical companies, how to move toward compliance prevention? proxy How can the dealers learn from the operating model of the CSO benchmarking company that has been successfully listed in the industry? How to make the CSO company return to its original source and make the truly compliant and legal CSO promotion company bigger and stronger?
On June 14, the State Administration of Taxation issuedenterprise The Announcement of the Measures for the Administration of Income Tax Deduction Certificates (hereinafter referred to as the “Measures”) puts forward a systematic and comprehensive request for the 'pre-tax deduction certificate' (known as the 'evidence chain' in the industry). The “Measures” proposed for the evidence chain. 'The general requirements of authenticity, legitimacy, and relevance principles should be followed. The invoices of pharmaceutical companies and CSO institutions must be 'four consistent'. How can pharmaceutical companies verify the authenticity of 'CSO business flow'? What business evidence is required? How is the expenditure handled?
The two-vote system has been fully implemented. The return of the pharmaceutical companies to the transformation of the base price has turned higher. The sales expenses are extremely high. The ratio is seriously unbalanced. The risk of tax-related inspection is huge. How to rationally plan the structure and proportion of expenses? How to regulate the invoices provided by the agents and salesmen? Regulatory? How does the commission pay for legal compliance?
